Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

July 25th 2024

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

FDA Grants Fast Track Designation to Ozuriftamab Vedotin in Recurrent/Metastatic HNSCC

July 23rd 2024

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC

July 18th 2024

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

Dr Olazagasti on Disparities in Lung Cancer Screening Rates for Hispanic Head and Neck Cancer Survivors

July 18th 2024

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Dr Sun on Managing TEAEs of Tisotumab Vedotin in Recurrent/Metastatic HSNCC

July 16th 2024

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Dr Kirtane on the Design of a Phase 1b Trial of Tbio4101 Plus Pembrolizumab in HNSCC

July 15th 2024

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Dr Mehra on the Implications of the E3311 Trial in HPV+ Oropharynx Cancer

July 11th 2024

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

First-line Eftilagimod Alpha Plus Pembrolizumab Generates Favorable ORR in PD-L1–Negative HNSCC

July 11th 2024

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Dr Wirth on Questions About Selpercatinib Use in Advanced RET Fusion+ Thyroid Cancer

July 11th 2024

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Dr Wirth on the LIBRETTO-001 Trial of Selpercatinib in RET Fusion+ Thyroid Cancer

July 3rd 2024

Lori Wirth, MD, discusses the LIBRETTO-001 trial of selpercatinib for patients with advanced or metastatic RET fusion–positive thyroid cancer.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

ASTRO Issues Clinical Practice Guideline For Radiation Therapy in HPV-Associated OPSCC

July 3rd 2024

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer

June 28th 2024

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

Ficerafusp Alfa/Pembrolizumab Demonstrates Clinically Meaningful Activity in Metastatic HNSCC

June 27th 2024

The bifunctional antibody ficerafusp alfa plus pembrolizumab generated clinically meaningful activity in HPV–recurrent/metastatic HNSCC.

Dr Olazagasti on Culturally Tailored Lung Cancer Screening for Hispanic Head and Neck Cancer Survivors

June 26th 2024

Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.

Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCC

June 24th 2024

Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.

Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancer

June 21st 2024

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Dr Kirtane on an Investigation of TILs Plus Pembrolizumab in Advanced HNSCC

June 20th 2024

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

Dr Mattes on the Mechanism of Action of Ipatasertib in HNSCC

June 20th 2024

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.